{"id":13724,"date":"2018-01-18T11:03:41","date_gmt":"2018-01-18T11:03:41","guid":{"rendered":"https:\/\/celonpharma.com\/?p=13724"},"modified":"2022-10-19T14:46:27","modified_gmt":"2022-10-19T14:46:27","slug":"amdbp","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/amdbp\/","title":{"rendered":"AMDBP"},"content":{"rendered":"
\"\"<\/div>\n

AMDBP \u2013 Development of a production platform for biosimilars based on CHO cells and an innovative expression system and preclinical and clinical development of a biosimilar drug based on a Fab fragment.
\n.<\/h2>\n

Funding Agreement No.: POIR.01.02.00-00-0010\/17-00 under Measure 1.2: \u201cSectoral R&D programmes\u201d
\nDate of the contract conclusion: 12.12.2017<\/p>\n

The aim of the project is designing an innovative production technology based on CHO cells and an innovative expression system of a biosimilar drug to ranibizumab used in treatment of retinal disorders. In contrast to the reference drug available on the market (produced in a bacterial expression system), this process will be carried out in a mammalian expression system in a CHO line. The reference drug consists of a fragment of an antibody binding an antigen (Fab) obtained from the same initial mouse antibody as bevacizumab, a cancer drug available to the market. This is why the applicant envisioned its production using a mammalian expression system, which will significantly lower the costs and enhance its safety and immunogenicity while maintaining the same biological activity. The project will result in development and marketing of a biosimilar drug used in treatment of retinal disorders. Such disorders constitute an enormous social problem, especially since they often affect low income patients. The implementation of the project results will considerably decrease the price of the newest generation of drugs, thus making them more available to patients, which will translate into lower socioeconomic costs of the problem. The project will be carried out in 6 stages during 55 months.
\nThe last stage of the project will focus on development works, i.a. clinical trials, preparing CTA documentation and marketing authorisation documents. The applicant\u2019s in-depth knowledge and experience as well as cooperation with domestic research institutions will facilitate the completion of its aims and objectives. The innovativeness of the project results will be certified with relevant patents.
\nTotal value of the\u00a0AMDBP project:<\/strong> 38\u00a0366\u00a0659,20 PLN
\nTotal value of funding:\u00a0<\/strong>24\u00a0783\u00a0037,60 PLN<\/p>\n","protected":false},"excerpt":{"rendered":"

AMDBP \u2013 Development of a production platform for biosimilars based on CHO cells and an innovative expression system and preclinical and clinical development of a biosimilar drug based on a Fab fragment.<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[98],"tags":[],"class_list":["post-13724","post","type-post","status-publish","format-standard","hentry","category-ue-co-financed-projects-implemented"],"acf":[],"yoast_head":"\nAMDBP - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/amdbp\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AMDBP - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"AMDBP \u2013 Development of a production platform for biosimilars based on CHO cells and an innovative expression system and preclinical and clinical development of a biosimilar drug based on a Fab fragment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/amdbp\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-18T11:03:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-19T14:46:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png\" \/>\n<meta name=\"author\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/\"},\"author\":{\"name\":\"S\u0142awomir Ni\u017cnik\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"headline\":\"AMDBP\",\"datePublished\":\"2018-01-18T11:03:41+00:00\",\"dateModified\":\"2022-10-19T14:46:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/\"},\"wordCount\":322,\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"articleSection\":[\"UE - co-financed projects implemented\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/\",\"name\":\"AMDBP - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"datePublished\":\"2018-01-18T11:03:41+00:00\",\"dateModified\":\"2022-10-19T14:46:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/#primaryimage\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\",\"contentUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/1178-106-max-1024x92.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/amdbp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AMDBP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\",\"name\":\"S\u0142awomir Ni\u017cnik\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AMDBP - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/amdbp\/","og_locale":"en_US","og_type":"article","og_title":"AMDBP - Celon Pharma","og_description":"AMDBP \u2013 Development of a production platform for biosimilars based on CHO cells and an innovative expression system and preclinical and clinical development of a biosimilar drug based on a Fab fragment.","og_url":"https:\/\/celonpharma.com\/en\/amdbp\/","og_site_name":"Celon Pharma","article_published_time":"2018-01-18T11:03:41+00:00","article_modified_time":"2022-10-19T14:46:27+00:00","og_image":[{"url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","type":"","width":"","height":""}],"author":"S\u0142awomir Ni\u017cnik","twitter_card":"summary_large_image","twitter_misc":{"Written by":"S\u0142awomir Ni\u017cnik","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/amdbp\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/amdbp\/"},"author":{"name":"S\u0142awomir Ni\u017cnik","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"headline":"AMDBP","datePublished":"2018-01-18T11:03:41+00:00","dateModified":"2022-10-19T14:46:27+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/amdbp\/"},"wordCount":322,"image":{"@id":"https:\/\/celonpharma.com\/en\/amdbp\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","articleSection":["UE - co-financed projects implemented"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/amdbp\/","url":"https:\/\/celonpharma.com\/en\/amdbp\/","name":"AMDBP - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/celonpharma.com\/en\/amdbp\/#primaryimage"},"image":{"@id":"https:\/\/celonpharma.com\/en\/amdbp\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","datePublished":"2018-01-18T11:03:41+00:00","dateModified":"2022-10-19T14:46:27+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/amdbp\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/amdbp\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/celonpharma.com\/en\/amdbp\/#primaryimage","url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png","contentUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2022\/10\/1178-106-max-1024x92.png"},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/amdbp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"AMDBP"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338","name":"S\u0142awomir Ni\u017cnik"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=13724"}],"version-history":[{"count":3,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13724\/revisions"}],"predecessor-version":[{"id":26424,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13724\/revisions\/26424"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=13724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=13724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=13724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}